577-nm Diode Laser in the Treatment of Non -Inflammatory Acne

August 15, 2026 updated by: Hala Hassan Shehata Ahmed, Al-Azhar University

Effectiveness and Safety of 577-nm Diode Laser in the Treatment of Non -Inflammatory Acne

The aim of this study is to evaluate the clinical efficacy and safety of the 577 nm diode laser in the treatment of non -inflammatory acne.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Acne vulgaris is a prevalent skin condition categorized into two types: non-inflammatory (comedones) and inflammatory (papules, pustules, and nodules). It primarily affects adolescents and young adults, often leading to scarring and diminished self-esteem. Over 80% of teenagers experience acne, which can continue into adulthood. The psychological impacts are significant, as many individuals experience reduced self-esteem and heightened anxiety. Effective treatment and management are essential for enhancing the quality of life for those affected.

The pathogenesis of acne is influenced by multiple factors, including excess sebum production, follicular keratinization, Propionibacterium acnes colonization, and inflammation. Acne treatments typically include topical and oral medications. Topical options, such as retinoids and antibiotics, require frequent application, which can affect patient compliance. Topical antibiotics often show poor efficacy and can lead to recurrence. Additionally, topical retinoids may cause irritation, while oral medications can have more severe side effects. Systemic isotretinoin is effective but associated with high costs and significant side effects, including teratogenicity and dryness.

Laser treatment for acne, particularly the inflammatory type, has gained significant popularity in recent years. This therapy effectively reduces acne lesions by inhibiting overactive sebaceous glands and alleviating inflammation. The mechanism is believed to involve the activation of porphyrins produced by Propionibacterium acnes, leading to the destruction of their cell membranes. Lasers with a wavelength of 1064 nm have been specifically studied for acne treatment. Various laser systems, such as near-infrared lasers and radiofrequency devices, effectively destroy sebaceous glands. Additionally, light sources like blue lights and intense pulsed light (IPL) are being increasingly incorporated into standard medical treatments to improve therapeutic outcomes.

Several types of lasers have been used to treat acne vulgaris in recent years and have shown great results. IPL and the 1,064-nm Nd:YAG laser are effective in treating inflammatory facial acne vulgaris, with no significant difference in their effects on facial acne lesions. Nd:YAG laser treatment also leads to a reduction in the total number of comedones, similar to the improvement observed with inflammatory lesions.

Vascular lasers, particularly a 577-nm high-power optically pumped semiconductor laser, are effective and safe for treating inflammatory lesions, decreasing Propionibacterium acnes, and reducing the size and function of the pilosebaceous unit.

Effective management of acne comedones often requires consistent use of topical treatments for several weeks to see significant improvement. If over-the-counter options take a long time and require considerable effort, it may be beneficial to explore other therapeutic avenues.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Assuit
      • Asyut, Assuit, Egypt, 71511
        • Azhar Assuit university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients with acne comedones
  • Patients' ages range from 18-40 years.
  • Minimum 10 comedonal lesions on both half of the face

Exclusion Criteria:

  • Patients with systemic disease interfere with healing.
  • Patients with Photosensitivity.
  • Pregnant or lactating females.
  • Previous topical, systemic, laser, surgical treatment and comedogenic drugs in the last 3 months.
  • Skin cancer or suspicious lesions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: All patients will be treated with sessions of the 577 nm Diode laser on one side of the face
All patients will be treated with sessions of the 577 nm Diode laser on one side of the face and on the other side serve as a control
All patients will be treated with sessions of the 577 nm Diode laser on one side of the face and on the other side serve as a control
No Intervention: other side of the face serve as a control arm without interventions
All patients will be treated with sessions of the 577 nm Diode laser on one side of the face and on the other side serve as a control without any interventions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Reduction in the number of comedones, measured through clinical assessment before and after treatment
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 29, 2025

Primary Completion (Actual)

November 1, 2025

Study Completion (Actual)

February 1, 2026

Study Registration Dates

First Submitted

March 27, 2025

First Submitted That Met QC Criteria

March 27, 2025

First Posted (Actual)

April 3, 2025

Study Record Updates

Last Update Posted (Actual)

August 18, 2026

Last Update Submitted That Met QC Criteria

August 15, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe